Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioPorto A/S Updates on FY 2013 Guidance

Friday, 2 Aug 2013 05:08am EDT 

BioPorto A/S announced that it expects fiscal year 2013 revenues to be on a par with fiscal year 2012. The Company previously announced expectations for a loss slightly greater in 2013 than in 2012 due to the initiation of clinical trials for more than DKK 2.5 million. This expectation is specified to a loss of approximately between DKK 18 million and DKK 21 million, in which costs related to the change of CEO in the order of DKK 2 million is included. 

Company Quote

-0.06 -3.39%
27 Mar 2015